Ticker League

Total Debt for Regeneron Pharmaceuticals (REGN)

As of · Reported

Metric

Latest period

$2.71B

YoY change

+0.1%

5Y CAGR

+0.1%

Peak year (2025)

$2.71B

Total Debt history chart for Regeneron Pharmaceuticals (REGN) from 1990 to 2025

Latest: $2.71B

Total Debt growth chart for Regeneron Pharmaceuticals (REGN) from 1990 to 2025

Latest: +0.1%

Total Debt history table for Regeneron Pharmaceuticals (REGN) from 1990 to 2025

  • 2025$2.71B+0.1%
  • 2024$2.70B+0.1%
  • 2023$2.70B+0.1%
  • 2022$2.70B+0.1%
  • 2021$2.70B+0.1%
  • 2020$2.70B+277.6%
  • 2019$713.90M+0.8%
  • 2018$708.50M+0.7%
  • 2017$703.45M+46.2%
  • 2016$481.13M+28.1%
  • 2015$375.51M-18.2%
  • 2014$459.06M-9.2%
  • 2013$505.51M+10.5%
  • 2012$457.33M+5.0%
  • 2011$435.53M+172.2%
  • 2010$160.03M+46.8%
  • 2009$109.02M+2040.6%
  • 2008$5.09M-97.5%
  • 2007$202.29M+1.1%
  • 2006$200.00M0.0%
  • 2005$200.00M0.0%
  • 2004$200.00M-6.5%
  • 2003$213.82M+6.8%
  • 2002$200.15M-0.2%
  • 2001$200.58M+7381.4%
  • 2000$2.68M-34.6%
  • 1999$4.10M-2.4%
  • 1998$4.20M-25.0%
  • 1997$5.60M-35.6%
  • 1996$8.70M-8.4%
  • 1995$9.50M-22.8%
  • 1994$12.30M+64.0%
  • 1993$7.50M+10.3%
  • 1992$6.80M+142.9%
  • 1991$2.80M—
  • 1990$0.00—

Total Debt values are taken from Regeneron Pharmaceuticals's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About Total Debt at Regeneron Pharmaceuticals (REGN)

According to Regeneron Pharmaceuticals's latest reported financial statements, the company's latest reported total debt is $2.71B. Total debt is the sum of short-term and long-term interest-bearing borrowings on the balance sheet (notes, bonds, term loans, lease liabilities). Useful for leverage and refinancing risk — compare with cash on hand for net leverage, and total liabilities for the broader obligations picture.

Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .

As of the 2025 fiscal year, Regeneron Pharmaceuticals (REGN) reported total debt of $2.71B – edged up 0.1% year-over-year.

Looking at the 2020–2025 (5 years) stretch, Regeneron Pharmaceuticals total debt compounded at +0.1% per year, with mixed annual results across the window.

Across the available history, total debt reached its high of $2.71B in 2025 and its low of $0.00 in 1990.

Regeneron Pharmaceuticals Total Debt by Year

Regeneron Pharmaceuticals Total Debt 2025: $2.71B

Regeneron Pharmaceuticals posted total debt of $2.71B in 2025, edged up 0.1% from 2024. This figure represents the highest annual value in the available history.

Regeneron Pharmaceuticals Total Debt 2024: $2.70B

In 2024, Regeneron Pharmaceuticals reported total debt of $2.70B, edged up 0.1% from 2023.

Regeneron Pharmaceuticals Total Debt 2023: $2.70B

Regeneron Pharmaceuticals total debt in 2023 was $2.70B, edged up 0.1% from 2022.

Regeneron Pharmaceuticals Total Debt 2022: $2.70B

2022's total debt for Regeneron Pharmaceuticals came in at $2.70B, edged up 0.1% from 2021.

Regeneron Pharmaceuticals Total Debt 2021: $2.70B

Regeneron Pharmaceuticals total debt in 2021 was $2.70B.

See more financial history for Regeneron Pharmaceuticals (REGN).

Sector peers by Total Debt

Healthcare peers of Regeneron Pharmaceuticals (REGN), ranked by their latest total debt

Frequently asked questions

Regeneron Pharmaceuticals (REGN) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation